All In Biotech

Drug Trial Radar · NCT07076095

A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer

A Phase II/III Study to Compare IBB0979 in Combination With Topotecan Versus Topotecan in Subjects With Relapsed Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Aug 1, 2025

Primary completion

Aug 1, 2028

Study completion Aug 1, 2031

Sponsor

Sponsor type
Industry
Collaborators
Zhengzhou University
First posted
Jul 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to compare the efficacy and safety of IBB0979 in combination with topotecan versus topotecan in subjects with relapsed small cell lung cancer (SCLC).

Conditions

  • Small Cell Lung Cancer

Interventions

  • IBB0979Drug

    bifunctional antibody-cytokine fusion protein that targets B7-H3 and IL-10 receptor

  • topotecan hydrochloride for injectionDrug

    Topotecan hydrochloride will be administered intravenously per prescribing information.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of adverse events (AEs) and SAEs (Phase II)Time frame: Approximately within 36 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.